Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Avonex

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avonex was produced by Biogen Idec.

Novartis’ Extavia evades NICE restrictions on MS drugs

Novartis’ Extavia evades NICE restrictions on MS drugs But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down. ... The appraisal rejected four other interferons - Biogen’s Avonex and long-acting variant Plegridy, Bayer’s Betaferon, and Merck Serono’s Rebif - as well as Teva’s

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta Zinbryta is dosed once a month - less frequently than other MS drugs such as Biogen's own Plegridy and Avonex - and is formulated as a subcutaneous injection that can be administered

Biogen's CEO Scangos to step down

Biogen's CEO Scangos to step down 2015, although older injectable MS treatment Avonex (interferon-beta-1a) fell 2% to $606m. ... Long-acting Avonex follow-up Plegridy continued to gain ground - with sales up 65% to $123m - and there were also strong gains for Biogen's haemophilia drugs

Biogen multiple sclerosis drug flunks clinical trial

Biogen multiple sclerosis drug flunks clinical trial interferon products Avonex and Plegridy and lower-than-hoped-for volume growth for oral therapy Tecfidera (dimethyl glutamate). .

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Biogen and AbbVie bag FDA approval for multiple sclerosis drug Zinbryta (daclizumab) is dosed once a month – in comparison with fortnightly and weekly for Biogen's Plegridy and Avonex, respectively - and is designed to be administered as a subcutaneous injection by ... patients by 45% when compared with Avonex

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics